MSMarisel Segarra-Newnham

Marisel Segarra-Newnham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marisel Segarra-Newnham has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Shari S Tagoff

    Shari S Tagoff PharmD, Pharmacy Practice Resident, Veterans Affairs Medical Center, West Palm Beach

    2 shared publications
  • Bryan D Volpp

    1 shared publication
  • David Parra

    Pharmacy Department, Patient Support Service, Veterans Affairs Medical Center, West Palm Beach, Florida

    1 shared publication
  • Ellen M Martin-Cooper

    Ellen M Martin-Cooper PharmD, Pharmacy Practice Resident, VAMC, West Palm Beach

    1 shared publication
  • Ellen M. Martin‐Cooper

    Pharmacy Department, Patient Support Service, Veterans Affairs Medical Center, West Palm Beach, Florida

    1 shared publication
  • Martha I. Salazar

    College of Pharmacy, University of Florida, Gainesville, Florida

    1 shared publication

Latest Publications

  • Effectiveness and Hepatotoxicity of Statins in Men Seropositive for Hepatitis C Virus

    by Marisel Segarra‐Newnham, David Parra, Ellen M. Martin‐Cooper

    Study Objective. To evaluate the effectiveness and hepatotoxicity of statins in patients who are seropositive for hepatitis C virus (HCV).Design. Retrospective review of a registry of patients with HCVSetting. Veterans Affairs Medical Center.Patients. One hundred forty‐six male patients who were seropositive for HCV and had received statin therapy between January 1, 1995, and September 9, 2003.Measurements and Main Results. Demographic and clinical data were collected for each patient; lipid and alanine aminotransferase (ALT) levels at baseline (within 6 mo of starting a statin), at 3 and 6 months after starting a statin, and at long‐term follow‐up (mean 22 mo) were also recorded. The primary efficacy end point was a significant decrease from baseline to long‐term follow‐up low‐density lipoprotein cholesterol (LDL) level; the primary safety end point was a significant increase from baseline in ALT level. The mean change in LDL level was a reduction of 22% (pConclusion. In men seropositive for HCV, statins were effective in reducing LDL levels and did not result in significant increases in ALT levels from baseline. Thus, statin therapy should be considered for patients with HCV who are at risk for coronary heart disease and do not have significantly elevated serum transaminase levels at baseline.


  • Antibiotic Lock Technique: A Review of the Literature

    by Marisel Segarra-Newnham, Ellen M Martin-Cooper

    OBJECTIVE: To review the literature on the use of the antibiotic lock technique (ALT) as a treatment option for patients with highly needed catheters. DATA SOURCES: MEDLINE and International Pharmaceutical Abstracts were searched (1980–August 2004). Search terms included antibiotic lock, catheter infection, and topical treatment. STUDY SELECTION AND DATA EXTRACTION: Articles describing use of ALT in the treatment of catheter infections in humans and studies evaluating in vitro stability of antibiotics were included. DATA SYNTHESIS: ALT has been used in patients with highly needed catheters, usually for parenteral nutrition, cancer chemotherapy, or dialysis. Catheters are considered highly needed when removal is not feasible or desirable due to lack of alternative injection sites for required therapy. Success rates in saving the infected catheter have been variable and may depend on the infecting organism. In addition, there are conflicting data in terms of compatibility of antibiotics with heparin solutions. CONCLUSIONS: Consensus appears to be that the ALT can be tried for patients with highly needed catheters when infection with coagulase-negative staphylococci is documented and no systemic signs of sepsis, such as hypotension, are evident. Most of these patients are likely to need systemic therapy as well. Infection of the catheter associated with systemic gram-negative bacteremia or fungemia will most likely require removal of the catheter to prevent systemic complications. Additional research with the ALT is warranted given unanswered questions.


  • Treating Veterans for Helicobacter Pylori Infection: Retrospective Evaluation of Long-term Outcomes

    by Marisel Segarra-Newnham

    Purpose: This study documented the long-term outcomes of patients treated in a pharmacist-managed Helicobacter pylori (HP) clinic. Background: An HP clinic was created in 1996 at a Veterans Affairs (VA) hospital. Patients received clarithromycin/amoxicillin-based therapy according to the clinic protocol. Clarithromycin use was restricted to treatment of HP infection. Metronidazole was used instead of amoxicillin in penicillin allergic patients. Results at 1 year showed that 53% of the patients were able to discontinue chronic heartburn therapy. Outcomes beyond 1 year were not established. Methods: The electronic records of patients treated at the HP clinic from June 1996 to March 2001 were evaluated. Patients with at least 2 years of follow-up information were included. Baseline demographic and long-term outcome data were collected. Discontinuation rate, failure rate, and need for retreatment were evaluated. Results: Of 229 patients treated during the period studied, at least 2 years of data was available for 198 individuals. Of these, 177 were men and 21 were women. Three of the 198 patients (1.5%) were unable to complete antibiotic therapy. Five patients (2.5%), two of them women, failed an initial course to eradicate HP. After treatment with bismuth-based therapy, four of these five patients showed documented eradication of infection. Forty-four percent of patients were off chronic therapy at the time of last review. Conclusions: A pharmacist-managed HP treatment clinic can facilitate discontinuation of chronic acid suppressive therapy in more than a third of patients. A low treatment failure rate — below the national average for clarithromycin-based regimens — was found in our population.


  • Probable Vancomycin-Induced Neutropenia

    by Marisel Segarra-Newnham, Shari S Tagoff

    OBJECTIVE: To report a case of vancomycin-induced neutropenia and provide a review of the literature. CASE SUMMARY: A 64-year-old white man was treated with intravenous vancomycin 1.5 g/day for finger osteomyelitis. He developed neutropenia after 21 days of vancomycin therapy. The absolute neutrophil count reached a nadir of 418 cells/mm 3 during vancomycin use and returned to normal 7 days after its discontinuation. The eosinophil count was also elevated during the neutropenic episode and probably related to vancomycin. Based on the Naranjo probability scale, the reaction was probably related to vancomycin use. DISCUSSION: Articles describing cases of vancomycin-induced neutropenia were identified. All patients developed neutropenia as a result of vancomycin therapy 12 days. Neutrophil counts generally increased following discontinuation of vancomycin. One article reported successful resolution of neutropenia and infection by switching the patient's therapy to the structurally related antibiotic agent teicoplanin. Other patients were continued on vancomycin therapy, and neutropenia was treated with moderate to good success with filgrastim. Rechallenge was not generally attempted. The mechanism of neutropenia caused by vancomycin is unclear, but appears to be immune-mediated. CONCLUSIONS: Vancomycin therapy should not be prolonged unless absolutely necessary, and therapy should be reserved for patients with clear indications for the drug, such as infections due to gram-positive organisms resistant to other therapies. Patients should have periodic assessment of white blood cell and neutrophil counts with consideration to discontinue vancomycin if neutropenia develops.


  • Valacyclovir and Postherpetic Neuralgia

    by Marisel Segarra-Newnham, Shari S Tagoff

    Objective: To describe the role of valacyclovir in the treatment of acute herpes zoster pain and its effect in postherpetic neuralgia. Data Sources: A literature search was conducted on MEDLINE (1980–October 2003). Search terms included valacyclovir, postherpetic neuralgia, treatment, acyclovir, and valacyclovir. Study Selection and Data Extraction: Articles describing use of valacyclovir in the treatment of herpes zoster, with focus upon alleviation of acute zoster pain and postherpetic neuralgia, and articles describing use of valacyclovir for this indication in comparison with other antivirals were evaluated. Data Synthesis: Four studies discussing the use of valacyclovir in the treatment of herpes zoster with focus on herpetic pain and postherpetic neuralgia were identified. All of these studies reported that valacyclovir is an effective treatment for herpes zoster and alleviates associated pain significantly faster than acyclovir, presumably due to its greater bioavailability. Valacyclovir likely results in a higher adherence rate than acyclovir because it is dosed 3 versus 5 times daily. Interestingly, the severity of pain was not significantly different between the 2 treatments, only the duration. Finally, one study showed that valacyclovir is equally as effective as famciclovir in alleviating pain associated with herpes zoster. Conclusions: Valacyclovir 1 g given orally 3 times a day for 7 days is effective in the treatment of herpes zoster. It is superior to acyclovir 800 mg given orally 5 times a day for 7 days and equivalent to famciclovir 500 mg given orally 3 times a day for 7 days in alleviating acute zoster pain and postherpetic neuralgia.


  • Tracking Vaccination Rates among HIV-Positive Patients with a Computerized Reminder System

    by Marisel Segarra-Newnham

    Objective: This study deterimined vaccination rates at a Veterans Affairs HIV clinic before and after the 1997 implementation of a computerized reminder system. Methods: Before implementation of a computerized reminder system, vaccinations were not always recorded on patients' medical records. After implementation, vaccinations were documented in the computer record and the system alerted providers when patients became due for a pneumococcal vaccine, tetanus booster, or other immunization. Charts for all patients (n = 211) enrolled in the HIV clinic were assessed for vaccination dates. Vaccination rates for patients (n = 71) enrolled before 1997 were compared with rates for patients (n = 140) enrolled after the computerized system was installed. The new system enabled the clinical pharmacist to monitor vaccination rates on a quarterly basis and facilitate patient appointments. Results: Vaccination rates for patients enrolled before 1997 were 100% for initial pneumococcal vaccination and 100% for tetanus. Seventy-six percent of patients due for a pneumococcal vaccine booster had received it. In contrast, patients enrolled after 1997 had vaccination rates of 94% for pneumococcal vaccine; eight recently enrolled patients did not have documentation of vaccination. The clinical pharmacist scheduled these patients and the rate increased to 97%. Due to a product shortage, only 61% of patients enrolled after 1997 had received tetanus vaccine. Conclusions: A computerized reminder system allows for reliable tracking of vaccination rates and can be used by pharmacists to improve preventive care for HIV-positive patients. Overall vaccination rates were well above the national norm.


  • Valganciclovir: A New Oral Alternative for Cytomegalovirus Retinitis in Human Immunodeficiency Virus‐Seropositive Individuals

    by Marisel Segarra‐Newnham, Martha I. Salazar

    Oral valganciclovir recently was approved by the Food and Drug Administration for treatment of cytomegalovirus (CMV) retinitis. We performed MEDLINE (June 1998–May 2002) and AIDSLINE (June 1998–December 2000) searches of available information on valganciclovir, and the drug's prescribing information was used to identify relevant articles. Additional studies, case reports, reviews, and abstracts were identified from references in the reviewed literature. Most of the information was obtained from abstracts or product labeling, since few trials have been published in the medical literature. Valganciclovir is a prodrug of ganciclovir and has been shown to have significantly higher oral absorption than ganciclovir capsules. One short‐term study found valganciclovir to be as effective as intravenous ganciclovir in treating CMV retinitis. Recommended dosages for patients with normal renal function are valganciclovir 900 mg twice/day for induction and 900 mg once/day for maintenance. Side effects are similar to those of intravenous ganciclovir and require periodic monitoring of complete blood count and renal function. Given the need for lifelong therapy for CMV retinitis in some human immunodeficiency virus‐positive patients, valganciclovir is a welcome alternative to long‐term administration of intravenous antivirals.


  • Preventing Medication Errors with a “Pharmacy Admission Note” for HIV-Positive Patients

    by Marisel Segarra-Newnham

    Purpose: To describe the utility of a clinical pharmacist's evaluation of HIV-positive patients upon hospital admission. Methods: At our Veterans Affairs Medical Center, HIV-positive patients are assigned to the Infectious Diseases (ID) team for clinical follow-up. Since March of 1999, however, general medicine staff admit HIV-positive patients to the facility. To decrease possible medication errors, communicate medication regimens, and provide continuity of care, the ID clinical pharmacist writes a “Pharmacy Admission Note” for each HIV-positive patient. A 2-year retrospective review of these notes was conducted. Results: Fifty-one patients were admitted during the study period. The ID clinical pharmacist provided 317 recommendations (median 4.2 per patient). One hundred seventy-three recommendations were intended to avoid medication errors (55%). The most common potential errors were “medication no longer needed” (n = 65, 38%) and “decrease dose” (n = 50, 29%). Conclusions: The use of a Pharmacy Admission Note facilitates communication with the admitting teams, provides continuity of care, and prevents medication errors.


  • Retrospective Assessment of Possible Hypersensitivity Reactions to Abacavir

    by Marisel Segarra-Newnham, Bryan D Volpp

    Objective: To document the frequency of abacavir hypersensitivity reactions in HIV-positive patients followed in a Veterans Affairs outpatient clinic. Methods: Abacavir's manufacturer lists the incidence of hypersensitivity as 5%. We conducted a retrospective review of all patients in our clinic who received abacavir from January 1999 to December 1999 to document the rate of discontinuation of the drug due to possible hypersensitivity reactions. The duration of abacavir therapy, concomitant antiretrovirals, most recent CD4+ count, most recent viral load, number of antiretroviral regimens previously tried, and the number and types of new antiretrovirals started concomitant with abacavir were collected. Results: Of 24 patients analyzed, nine (38%) discontinued abacavir, with six (25%) having a potential hypersensitivity reaction. Four reactions were classified as probable and two as possible according to the Naranjo scale. Only one patient was hospitalized for the reaction. Patients who discontinued abacavir due to a hypersensitivity reaction had similar CD4+ counts, viral loads, and had received a similar number of antiretroviral regimens compared with patients who continued the drug. However, 67% of patients who discontinued abacavir due to a hypersensitivity reaction had at least one previously documented adverse event that led to the discontinuation of another antiretroviral, compared with 7% of the patients who continued the drug (p = 0.02). Conclusions: The frequency of possible hypersensitivity reactions to abacavir in patients seen in our HIV clinic is higher than the manufacturer's reported rate of 5%. These patients may be more prone to adverse reactions based on previous medication history and adverse events.